Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

686
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
686
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

764
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
764
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.3K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025.

Pigment cell & melanoma research·2026
Same author

Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.

Clinical genitourinary cancer·2026
Same author

Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumours.

European journal of cancer (Oxford, England : 1990)·2026
Same author

A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseases.

NPJ precision oncology·2026
Same author

<sup>177</sup>Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer.

Radiology·2026

Related Experiment Video

Updated: Apr 5, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Pembrolizumab.

Leila Khoja1, Marcus O Butler1, S Peter Kang2

  • 1Department of Medical Oncology, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON M5G 2M9 Canada.

Journal for Immunotherapy of Cancer
|August 20, 2015
PubMed
Summary
This summary is machine-generated.

Pembrolizumab, an anti-programmed death receptor 1 (PD-1) antibody, shows efficacy in treating metastatic melanoma and non-small cell lung cancer (NSCLC). Ongoing trials will further define its optimal use in various cancers.

Keywords:
Immune checkpoint blockadeLung cancerMelanomaPembrolizumabProgrammed death receptor 1Programmed death receptor ligand 1

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.2K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K

Related Experiment Videos

Last Updated: Apr 5, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.2K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • The approval of ipilimumab marked a new era in immuno-oncology.
  • Agents targeting the programmed death receptor 1 (PD-1)/programmed death receptor ligand 1 (PD-L1) axis have demonstrated significant activity in various cancers.
  • Pembrolizumab is an anti-PD-1 antibody with demonstrated efficacy.

Purpose of the Study:

  • To review the efficacy and toxicity profile of pembrolizumab.
  • To evaluate the future development and optimal use of pembrolizumab.
  • To discuss the role of pembrolizumab in treating melanoma and non-small cell lung cancer (NSCLC).

Main Methods:

  • Review of clinical trial data for pembrolizumab.
  • Analysis of efficacy and toxicity profiles.
  • Evaluation of ongoing and future clinical trials.

Main Results:

  • Pembrolizumab is approved for unresectable or metastatic melanoma progressing after ipilimumab.
  • Pembrolizumab has breakthrough status for EGFR/ALK-negative non-small cell lung cancer (NSCLC) progressing after chemotherapy.
  • Pivotal trials are ongoing to assess pembrolizumab's optimal use alone and in combination.

Conclusions:

  • Pembrolizumab represents a significant advancement in immuno-oncology.
  • Further research is needed to fully establish the role of pembrolizumab in cancer treatment.
  • Pembrolizumab holds promise for melanoma, NSCLC, and potentially other tumor types.